Condition
Uterine Serous Carcinoma
Total Trials
5
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Completed3
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04814108Phase 2CompletedPrimary
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT06369155Phase 2RecruitingPrimary
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT05902988Phase 1Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT04080284Phase 2Completed
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT04590248Phase 2CompletedPrimary
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Showing all 5 trials